Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond

Y Lee, E Puumala, N Robbins, LE Cowen - Chemical reviews, 2020 - ACS Publications
Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

Treatment strategies for cryptococcal infection: challenges, advances and future outlook

KR Iyer, NM Revie, C Fu, N Robbins… - Nature Reviews …, 2021 - nature.com
Cryptococcus spp., in particular Cryptococcus neoformans and Cryptococcus gattii, have an
enormous impact on human health worldwide. The global burden of cryptococcal meningitis …

Amphotericin B and other polyenes—Discovery, clinical use, mode of action and drug resistance

H Carolus, S Pierson, K Lagrou, P Van Dijck - Journal of Fungi, 2020 - mdpi.com
Although polyenes were the first broad spectrum antifungal drugs on the market, after 70
years they are still the gold standard to treat a variety of fungal infections. Polyenes such as …

Antifungal drugs: the current armamentarium and development of new agents

N Robbins, GD Wright, LE Cowen - Microbiology spectrum, 2016 - Am Soc Microbiol
Invasive fungal infections are becoming an increasingly important cause of human mortality
and morbidity, particularly for immunocompromised populations. The fungal pathogens …

Combinatorial strategies for combating invasive fungal infections

M Spitzer, N Robbins, GD Wright - Virulence, 2017 - Taylor & Francis
Invasive fungal infections are an important cause of human mortality and morbidity,
particularly for immunocompromised populations. However, there remains a paucity of …

Treatment of Cryptococcal meningitis: how have we got here and where are we going?

NTT Ngan, B Flower, JN Day - Drugs, 2022 - Springer
Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the
Cryptococcus genus. Exposure, through inhalation, is likely universal by adulthood, but …

[HTML][HTML] Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

P Van Dijck, J Sjollema, BPA Cammue, K Lagrou… - Microbial Cell, 2018 - ncbi.nlm.nih.gov
Unlike superficial fungal infections of the skin and nails, which are the most common fungal
diseases in humans, invasive fungal infections carry high morbidity and mortality …

Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design

BC Monk, AA Sagatova, P Hosseini, YN Ruma… - … et Biophysica Acta (BBA …, 2020 - Elsevier
The cytochrome P450 enzyme lanosterol 14α-demethylase (LDM) is the target of the azole
antifungals used widely in medicine and agriculture as prophylaxis or treatments of …

Molecular mechanisms governing antifungal drug resistance

Y Lee, N Robbins, LE Cowen - npj Antimicrobials and Resistance, 2023 - nature.com
Fungal pathogens are a severe public health problem. The leading causative agents of
systemic fungal infections include species from the Candida, Cryptococcus, and Aspergillus …

Characterization of Aspergillus fumigatus Extracellular Vesicles and Their Effects on Macrophages and Neutrophils Functions

JAM Souza, LM Baltazar, VM Carregal… - Frontiers in …, 2019 - frontiersin.org
Extracellular vesicles (EVs) has been considered an alternative process for intercellular
communication. EVs release by filamentous fungi and the role of vesicular secretion during …